PHARMACY

NACDS conference brings success, energy to the table

BY Allison Cerra

SAN DIEGO Uniting suppliers and manufacturers proved a success at National Association of Chain Drug Stores’ 2010 Marketplace Conference, which concluded Tuesday afternoon in San Diego.

Boasted as the largest convergence of drug, food, mass, club and value retailing in the United States, the NACDS Marketplace Conference featured new product showcases, category manager meet-and-greets and more. Representatives from such chains as Chain Drug Consortium, Costco, CVS Caremark, Kmart, Meijer, Shopko, Walgreens and Wegmans were present to provide visitors with industry insights.

Among the conference’s events were the Meet the Market program, Meet the Retailer/ How to Do Business With sessions and a product showcase on the exhibition floor. Evaluated by the retail attendees, winners of this year’s “Product Showcase” are:

  • Baby Care Company:    Bean-B-Clean Product:       Bean-B-Clean (Scalp Massaging Brush)         
  • Consumables Company:    Crunchies Food Co. Product:       Crunchies (all natural freeze dried fruits and veggies)         
  • Cosmetics and Fragrances Company:    U.S. Cotton, LLC Product:       Swisspers exfoliating cotton facial cleansing pads
  • General Merchandise Company:    FGX International Product:       LightSpecs by Foster Grant   
  • Healthcare/OTC Company:    TECNIMED Product:       Thermofocus, the original 5-1 non contact thermometer  
  • Home Healthcare Company:    Drive Medical Design & Manufacturing Product:       Glow & Go folding cane     
  • Personal Care/HBC Company:    Zeno Corp. Product:       Zeno Hot Spot blemish clearing device

“This year’s NACDS Marketplace Conference was an overall success and the atmosphere was full of energy,” said NACDS president and CEO Steve Anderson. “From the Meet the Market program to the education sessions and the exhibit floor, NACDS continues to provide attendees an effective and efficient meeting geared toward their needs.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Medco Health Solutions awarded by The Joint Commission

BY Alaric DeArment

FRANKLIN LAKES, N.J, Pharmacy benefit manager Medco Health Solutions has received a nod for its home care and pharmacy dispensing services from a healthcare standards and accrediting body, Medco said Tuesday.

The PBM said it received the Gold Seal of Approval from The Joint Commission. The recognition applies to services offered to clients and health plan members by Medco’s dispensing and call center pharmacies, and Medco said the approval places it among the leading organizations in its category. The organization’s accreditation process includes a review of 129 standards across 13 areas of focus, including treatment and services, rights and ethics, medication management and information management.

“This independent review validates the progress we have made in driving ever-higher standards in clinical excellence as we focus on closing the gaps in care for patients with chronic and complex conditions – patients who account for 96% of all drug spending and 75% of all medical costs,” Medco president and COO Kenny Klepper said. “The fact that in our reaccreditation The Joint Commission consistently found a high level of service across so many facilities speaks to the diligence and professionalism of Medco people at every level across our company.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Astellas completes acquisition of OSI

BY Alaric DeArment

TOKYO Japanese drug maker Astellas Pharma has completed its acquisition of OSI Pharmaceuticals, Astellas said Tuesday.

The $4 billion acquisition, announced in May, gives Astellas access to such drugs as the cancer drug Tarceva (erlotinib), which OSI co-markets with Roche division Genentech. OSI has lately been enrolling subjects for a late-stage clinical trial of OSI-906, a treatment for patients with adrenocortical carcinoma, a rare cancer of the adrenal gland, whose disease has spread to other parts of the body.

OSI will become a wholly owned subsidiary of Astellas through Astellas US Holding, a holding company.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?